Summary of Genmab's Conference Call Company Overview - **Company**: Genmab - **Event**: 46th Annual TD Cowen Healthcare Conference - **Key Speakers**: Anthony Pagano (CFO and Executive VP), Yaron Werber (Biotech Team) Core Industry Insights - **Oncology Focus**: Genmab is heavily invested in oncology, with three late-stage programs: EPKINLY, Rina-S, and pidocentimab, all of which have received FDA Breakthrough Therapy designations [2][3] - **Revenue Growth**: The company is experiencing strong revenue growth, particularly from proprietary products like EPKINLY and TIVDAK, with an increasing percentage of recurring revenue [7][8] - **Future Projections**: Genmab anticipates continued revenue growth into 2026 and beyond, driven by the success of its late-stage programs and a robust internal pipeline [3][4] Financial Performance - **Revenue Profile**: The revenue quality has improved year-over-year, with a notable increase in the contribution from proprietary products [7] - **TIVDAK Performance**: TIVDAK is expected to remain flat in terms of growth, contributing approximately $20 million, while EPKINLY is the primary driver of revenue growth [9][12] - **EPKINLY Sales**: EPKINLY had global sales of DKK 468 million last year, with expectations for growth in 2026, particularly in the second-line follicular lymphoma segment [17][19] Product Pipeline and Launches - **Rina-S and pidocentimab**: Both are expected to have registrational readouts in the second half of 2026, with potential launches in 2027 or 2028 [21][22] - **Market Potential**: Rina-S has a peak sales potential of over $2 billion, while EPKINLY is projected to reach $3 billion [27][31] - **Regulatory Process**: The timeline for product launches will depend on the regulatory process following data readouts [22][23] Debt and Profitability - **Debt Management**: Genmab took on $5.5 billion of debt for the Mirati acquisition and aims to reduce gross leverage to below 3 times by the end of 2027 [39][40] - **Profitability Commitment**: The company is committed to maintaining significant profitability in 2026 and 2027, focusing on efficient investments and operational productivity [40][41] Royalty Contributions - **Royalty Business**: The royalty revenue is primarily driven by DARZALEX and Kesimpta, with expectations for growth in 2026 [58][59] - **Emerging Products**: Tecfidera is expected to contribute positively, although it remains a smaller product in the portfolio [58] Additional Insights - **Synergy Realization**: The acquisition of Mirati is not primarily synergy-driven, but Genmab is looking for productivity improvements across its business [55][56] - **Clinical Trial Dynamics**: The company is open to adjusting clinical trial parameters to enhance outcomes and timelines [24][25] This summary encapsulates the key points discussed during the conference call, highlighting Genmab's strategic focus on oncology, financial performance, product pipeline, and future growth prospects.

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were approximately $599 million, including cabozantinib franchise net product revenues of $546.6 million [13] - Full year 2025 US CABO franchise net product revenues grew 17% to approximately $2.12 billion compared to 2024 [7] - GAAP net income for Q4 2025 was approximately $244.5 million, or $0.92 per share basic [16] - Non-GAAP net income for Q4 2025 was approximately $259.5 million, or $0.97 per share basic [17] - Cash and marketable securities at the end of 2025 were approximately $1.66 billion [17] Business Line Data and Key Metrics Changes - CABOMETYX maintained its position as the leading TKI for renal cell carcinoma (RCC) and neuroendocrine tumors, with Q4 2025 TRX volume growing 15% compared to Q4 2024 [19][20] - CABOMETYX's gross-to-net for Q4 2025 was 28.5%, lower than the previous quarter due to lower PHS and 340B volume [13] - Zanzalintinib is positioned as the next potential oncology franchise, with seven ongoing pivotal trials [10][24] Market Data and Key Metrics Changes - CABOMETYX's market share in the oral TKI segment grew from 43% to 46% from Q4 2024 to Q4 2025 [19] - The market basket growth rate for oral TKIs was 7% during the same period, indicating CABOMETYX outpaced the market [20] - The neuroendocrine tumor indication for CABOMETYX exceeded $100 million in revenue for 2025 [21] Company Strategy and Development Direction - The company aims to build a multi-franchise business in solid tumor oncology, focusing on cabozantinib and zanzalintinib [5][6] - The strategy includes expanding leadership in gastrointestinal (GI) indications while maintaining a strong position in genitourinary (GU) oncology [5] - Business development activities are focused on late-stage assets in GU and GI spaces, with a priority on pay-for-success transactions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building on the momentum from 2025 into 2026, with expectations for continued strong performance from the cabozantinib business [5] - The company is preparing for the potential launch of zanzalintinib, with a PDUFA date set for later in the year [22] - Management highlighted the significant unmet medical need in the third-line plus colorectal cancer setting, which zanzalintinib aims to address [22][26] Other Important Information - The company repurchased $954 million of its common stock in 2025, retiring approximately 24 million shares [17] - The remaining balance under the stock repurchase plan is approximately $590 million [18] Q&A Session Summary Question: How long will the company benefit from the small manufacturer discount for Zanza? - Management indicated that the small manufacturer exemptions are tied to having a single product as the majority revenue source, which is expected to remain the case for the foreseeable future [34][35] Question: Can you comment on recent 340B purchasing behavior? - Management noted variability in 340B purchasing behavior throughout 2025 and expects continued variability in 2026, which could impact gross-to-net [39][40] Question: What is the expected population size for STELLAR-316? - The estimated population for STELLAR-316 is around 20,000-25,000 patients who are MRD positive after definitive therapy [42][43] Question: What is the growth expectation for NET revenues? - Management expressed optimism about the growth potential in the neuroendocrine tumor segment, emphasizing the need to expand outreach in the community setting [45][47] Question: How does the company anticipate positive data impacting commercial strategy? - Positive data from ongoing trials is expected to enhance communication with physicians and clarify the benefits of the treatment for patients [56][58]